Welcome to our dedicated page for Artiva Biotherapeutics news (Ticker: ARTV), a resource for investors and traders seeking the latest updates and insights on Artiva Biotherapeutics stock.
Artiva Biotherapeutics develops cell therapies for autoimmune diseases and cancers, led by AlloNK® (AB-101), an allogeneic, off-the-shelf, non-genetically modified and cryopreserved NK cell therapy candidate. Company updates center on AlloNK clinical data in B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, and on its use with anti-CD20 monoclonal antibodies such as rituximab or obinutuzumab to drive B-cell depletion.
Recurring developments also cover quarterly and annual financial results, balance sheet disclosures, biotechnology conference participation, board and executive appointments, and equity award activity tied to Artiva’s public-company governance.
Artiva Biotherapeutics (ARTV) will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 a.m. EDT.
The company describes itself as a clinical-stage biotechnology company focused on developing cell therapies for debilitating autoimmune diseases. Live audio and an archived recording of this and other company presentations will be available via the Investors section of Artiva’s website. The archived webcast will remain accessible for replay for 90 days.
Artiva Biotherapeutics (ARTV) plans multiple AlloNK milestones and data disclosures through year-end 2026, including initiation of a Phase 3 trial in refractory rheumatoid arthritis (RA) in the second half of 2026.
The company expects updated Phase 2a basket trial data from at least 20 RA patients, each with ≥6 months follow-up and including ≥10 who would meet key Phase 3 eligibility criteria, plus data from ≥10 Sjögren disease and ≥5 systemic sclerosis patients. Artiva is initiating a Phase 3 randomized trial of AlloNK plus rituximab versus rituximab alone in ~150 refractory RA patients, with ACR50 at 6 months as the primary endpoint and topline results expected by end of 2028. The company cites FDA RMAT designation, alignment on a single registrational trial and a cash runway into 2029, extending beyond the planned topline readout.
Artiva Biotherapeutics (ARTV) will participate in two investor conferences in September 2026, featuring live fireside chats and investor meetings.
Management will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 10:20 am EDT, and at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 at 2:30 pm EDT. Webcasts and replays will be available in the Investors section of Artiva’s website for 90 days.
Artiva Biotherapeutics (Nasdaq: ARTV) reported second quarter 2026 results and clinical progress for lead NK-cell therapy AlloNK. At EULAR 2026, Phase 2a data in refractory rheumatoid arthritis (RA) showed 5 of 7 patients (71%) achieving ACR50 at six months, with no loss of response as of April 3, 2026.
Across 55 safety-evaluable autoimmune patients treated with AlloNK plus rituximab, no CRS, ICANS, AlloNK-related serious adverse events or treatment discontinuations due to adverse events were observed, and Grade ≥3 infection rate was 2%. The FDA granted RMAT designation for AlloNK plus rituximab in refractory RA, and Artiva plans to initiate a Phase 3 registrational trial in approximately 150 refractory RA patients in the second half of 2026.
Artiva completed an approximately $300 million underwritten offering in May 2026 and reported cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029. Q2 2026 research and development expenses were $21.9 million and net loss was $25.0 million, compared to $17.9 million and $21.3 million, respectively, in Q2 2025.
Artiva Biotherapeutics (Nasdaq: ARTV) announced that its Board Compensation Committee approved new employee inducement grants totaling 288,800 restricted stock units for 17 new employees under the company’s 2025 Inducement Plan, effective July 14, 2026, in reliance on Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years on quarterly vesting dates of February 15, May 15, August 15 and November 15. For each employee, 25% vests on the quarterly date closest to the one-year anniversary of their start date, and the remaining units vest in 12 equal quarterly installments, subject to continued employment and applicable grant documents.
Artiva Biotherapeutics (Nasdaq: ARTV) announced participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Management will join a fireside chat on June 30, 2026, at 3:30 p.m. EDT.
The live and archived audio webcast will be accessible for 90 days via the Investors section of Artiva’s website.
Artiva Biotherapeutics (Nasdaq: ARTV) reported new AlloNK (AB-101) data from five EULAR 2026 presentations and announced FDA RMAT designation for AlloNK plus rituximab in refractory rheumatoid arthritis (RA).
RA trials showed 71% ACR50 at six months, deep B-cell depletion across autoimmune diseases, and a tolerability profile supportive of outpatient use. A webcast is scheduled today at 8:15 a.m. EDT.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech focused on cell therapies for autoimmune diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on June 4, 2026 at 9:20 a.m. EDT. The live and archived audio webcast will be accessible via the Investors section of Artiva’s website for 90 days.
Artiva Biotherapeutics (Nasdaq:ARTV) will present multiple AlloNK (AB-101) data sets at the EULAR 2026 Congress in London, June 3–6, 2026.
Highlights include a late-breaking oral report of AlloNK + rituximab in 31 rheumatology patients, showing 71% ACR50 in refractory RA with ≥6 months follow-up and no relapses or new immunomodulatory agents.
Artiva Biotherapeutics (Nasdaq: ARTV) appointed Diego Miralles, M.D. as President and Head of Research and Development, effective May 18, 2026. He will lead advancement of AlloNK in autoimmune diseases, including preparation for a Phase 3 trial in refractory rheumatoid arthritis and a potential first BLA filing in 2029.
As an employment inducement, Miralles will receive options on 232,500 shares and 77,500 RSUs vesting over four years under Artiva’s 2025 Inducement Plan.